Evidence map›Paper›PMID 41304418›Full record

ArticlePolymers2025

Computational Modeling to Guide the Design of Mesalazine Nanoparticles Tailored for the Incorporation of Chitosan.

Leda Maria Gorla Robusti, Fernanda Isadora Boni, Leonardo M B Ferreira, Natália Noronha Ferreira, Deiver Alessandro Teixeira, Maria Palmira Daflon Gremião

Abstract read
In one paragraph

Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leda Maria Gorla RobustiSchool of Pharmaceutical Sciences, São Paulo State University, Rodovia Araraquara-Jaú Km 1, Araraquara 14800-903, SP, Brazil.
Fernanda Isadora BoniSchool of Pharmaceutical Sciences, University of São Paulo, Av. Professor Lineu Prestes, São Paulo 05508-000, SP, Brazil.
Leonardo M B FerreiraSchool of Pharmaceutical Sciences, São Paulo State University, Rodovia Araraquara-Jaú Km 1, Araraquara 14800-903, SP, Brazil.
Natália Noronha FerreiraSchool of Pharmaceutical Sciences, São Paulo State University, Rodovia Araraquara-Jaú Km 1, Araraquara 14800-903, SP, Brazil.
Deiver Alessandro TeixeiraFederal Institute Education, Science and Technology of Mato Grosso, IFMT, Avenida Ver. Juliano Costa Marques, s/n, Bela Vista, CEP, Cuiabá 78050-560, MT, Brazil.ORCID 0000-0003-2938-5648
Maria Palmira Daflon GremiãoSchool of Pharmaceutical Sciences, São Paulo State University, Rodovia Araraquara-Jaú Km 1, Araraquara 14800-903, SP, Brazil.ORCID 0000-0001-6950-7852

Funding

CNPq 465687/2014-8Fapesp 17/16324-0
6 · The paper itself

Abstract

The main objective of treatment with MSZ is to ensure that the drug reaches the colon, where it exerts its therapeutic effect. However, due to pH variation throughout the gastrointestinal tract and the risk of degradation or premature absorption, a considerable portion of the drug may not reach the colon in adequate concentrations. In this study, computational modeling was combined with experimental approaches for the design of MSZ nanoparticles (MSZ-NPs) suitable for chitosan (CS) incorporation. Quantum chemical calculations and molecular modeling revealed the importance of pH as a nucleation determinant and in the growth of the MSZ complexes. At pH~1.0, cationic clusters predominated, characterized by higher interaction energies and larger volumes/surface areas. At pH~4.0, zwitterionic clusters were stabilized, whereas at pH~6.0, anionic clusters formed the most compact assemblies, with the smallest calculated volume (4817 Å

Indexed as

chitosancomputational modelinginflammatory bowel diseasesmesalazine nanoparticlesmucoadhesion

Identifiers

PMID41304418
PMCPMC12655916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.